Compared to short-acting exenatide, long-acting ones such as dulaglutide, liraglutide, and exenatide once-weekly reduced hemoglobin A1c (HbA1c) by 0.51%, 0.45%, and 0.38% respectively [62]
The research team first demonstrated in experimental studies that enhancing glucagon-like peptide-1 (GLP-1) signalling can counteract key hallmarks of ageing across multiple organ systems, including the brain
Long-term studies of semaglutide found that after 68 weeks of treatment, patients actually reported better physical functioning and energy levels than when they started
they are rooted in complex physiological disruptions to your nervous system, cellular energy production, and metabolic pathways
Less common effects include fatigue, loss of appetite, or mild stomach discomfort